Status:
UNKNOWN
Individualized Pharmaceutical-care for Inpatients With Cancer Pain
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Cancer Pain
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant inpatients
Detailed Description
This study is a prospective multicenter randomized controlled study to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant inpatients.
Eligibility Criteria
Inclusion
- Patients aged 18 years or older;
- Histologically confirmed solid tumor;
- Diagnosed chronic cancer pain;
- Opioid-tolerant patients;
- Overall survival is expected to be over 3 months;
- Karnofsky performance score≥50;
- Willing and able to comply with the protocol
Exclusion
- Current pregnancy or breastfeeding;
- Patients diagnosed with non-cancer pain;
- Patients treated with patient-controlled analgesia;
- Patients with pathological fracture, gastrointestinal obstruction, severe infection, non-opioid related intractable constipation;
- Patients with mental disorder;
- Creatinine clearance rate \<15mL/min;
- ALT or AST ≥ 10 fold of upper limit of normal value
Key Trial Info
Start Date :
June 30 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2019
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03455023
Start Date
June 30 2018
End Date
June 30 2019
Last Update
January 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang cancer hospital
Hangzhou, Zhejiang, China, 310022